Lokesh Nigam

About

Dr. Lokesh Nigam is a biomedical researcher specializing in computational systems biology, structural biophysics, and translational oncology. He holds an M.Tech. and a Ph.D. from the School of Computational and Integrative Sciences at Jawaharlal Nehru University (JNU), India. His research integrates high-throughput computational drug design, multi-omics, advanced imaging, and experimental molecular biology to decipher oncogenic networks and develop novel therapeutics.

Dr. Nigam's doctoral research focused on rational peptide design and signaling network modeling, leading to the development of a ~168,000 peptide library licensed to Oncolyze Inc. (NY, USA). During his postdoctoral fellowships at The Translational Genomics Research Institute (TGen) and City of Hope Medical Center, he spearheaded mechanistic studies on OM-301, a synthetic polypeptide for Multiple Myeloma that earned U.S. FDA Orphan Drug Designation. His contributions have been recognized with the American Society of Hematology (ASH) Abstract Achievement Award and the IMS & Paula and Rodger Riney Foundation Translational Award. He has authored over 20 peer-reviewed publications across top oncology and biophysics journals.

Employment

• Translational Genomics Research Institute senior postdoctoral
  2023 - 2024
• City of Hope PostDoc
  2019 - 2023

Education

Education history is unavailable.

Projects & Funding

• JRF CSIR
  2008 - 2010

Publications (21)

• Identification of CD84 as a potent survival factor in acute myeloid leukemia
  Journal of Clinical Investigation 2025 DOI: 10.1172/jci176818
  +Save
• Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062
  Blood Advances 2025 DOI: 10.1182/bloodadvances.2024014225
  +Save
• Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
  Ada Donà, Theophilus Tandoh, Lokesh Nigam +18 more
  Journal of Hematology & Oncology ; Oncology 2025 DOI: 10.1186/s13045-024-01645-3
  +Save
• CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression
  Blood 2023 DOI: 10.1182/blood-2023-189901
  +Save
• Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma
  Blood 2023 DOI: 10.1182/blood-2023-190157
  +Save
• CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia
  Blood 2022 DOI: 10.1182/blood-2022-170300
  +Save
• Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses
  2022 DOI: 10.1101/2022.03.29.22272857
  +Save
• Cross Talk Between Oxidative Stress and p53 Family Members in Regulating Cancer
  Handbook of Oxidative Stress in Cancer Mechanistic Aspects 2022 DOI: 10.1007/978-981-15-9411-3_92
  +Save
• OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells
  Blood 2021 DOI: 10.1182/blood-2021-151506
  +Save
• Exploring the Molecular Level Interaction of Human Serum Albumin with Calcium Oxalate Monohydrate Crystals
  Priyadarshini, Abhishek Negi, Chetna Faujdar +2 more
  Protein and Peptide Letters 2021 DOI: 10.2174/0929866528666210930165426
  +Save
• Design and in vitro analysis of SIRT2 inhibitor targeting Parkinson's disease.
  Amrendra Pratap Singh, Lokesh Nigam, Yudhishthir Yadav +3 more
  Molecular diversity 2020 DOI: 10.1007/s11030-020-10116-z
  +Save
• Requirement of GTP binding for TIF‐90‐regulated ribosomal RNA synthesis and oncogenic activities in human colon cancer cells
  Journal of Cellular Physiology 2020 DOI: 10.1002/jcp.29661
  +Save
• CID-6033590 inhibits p38MAPK pathway and induces S-phase cell cycle arrest and apoptosis in DU145 and PC-3 cells
  Guru Prasad Sharma, Sumiran Kumar Gurung, Afreen Inam +7 more
  Toxicology in Vitro 2019 DOI: 10.1016/j.tiv.2019.06.003
  +Save
• Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative serum level evaluation and design of novel peptide inhibitor targeting the same
  Vishal Sahu, Lokesh Nigam, Vertica Agnihotri +5 more
  Cancer Research and Treatment 2019 DOI: 10.4143/crt.2018.105
  +Save
• Exploring the modulatory effect of albumin on calcium phosphate crystallization
  Priyadarshini Pathak, Devesh Raizada, Pragya Kumar +5 more
  Current Science 2019 DOI: 10.18520/cs/v117/i6/1083-1089
  +Save
• Design, synthesis of allosteric peptide activator for human SIRT1 and its biological evaluation in cellular model of Alzheimer's disease
  Rahul Kewal Kumar, Lokesh Nigam, Amrendra Pratap Singh +3 more
  European Journal of Medicinal Chemistry 2017 DOI: 10.1016/j.ejmech.2016.11.001
  +Save
• Interaction of biocompatible natural rosin-based surfactants with human serum albumin: A biophysical study
  Mohd Ishtikhar, Mohd Sajid Ali, Ayman M. Atta +4 more
  Journal of Luminescence 2015 DOI: 10.1016/j.jlumin.2015.06.012
  +Save
• The rational design of specific peptide inhibitor against p38α MAPK at allosteric-site: a therapeutic modality for HNSCC.
  Kamaldeep Gill, Lokesh Nigam, Ratnakar Singh +4 more
  PloS one 2014 DOI: 10.1371/journal.pone.0101525
  +Save
• Comparison of geometry and HOMO-LUMO of derivatives of p-benzoquinone using four quantum chemical theories
  International Journal of Cancer Research and Prevention 2014
  +Save
• Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase.
  Kamaldeep Gill, Abhay Kumar Singh, Vaishali Kapoor +8 more
  Biochimica et biophysica acta 2013 DOI: 10.1016/j.bbagen.2012.12.001
  +Save